cyclophosphamide, vincristine, prednisone, dacarbazine — Competitive Intelligence Brief

cyclophosphamide, vincristine, prednisone, dacarbazine (cyclophosphamide, vincristine, prednisone, dacarbazine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent, Vinca alkaloid, Corticosteroid. Area: Oncology.

phase 3 Alkylating agent, Vinca alkaloid, Corticosteroid Microtubules, DNA Oncology Small molecule

Target snapshot

cyclophosphamide, vincristine, prednisone, dacarbazine (cyclophosphamide, vincristine, prednisone, dacarbazine) — University of Giessen. Cyclophosphamide is an alkylating agent that interferes with DNA replication, vincristine is a vinca alkaloid that inhibits microtubule formation, prednisone is a corticosteroid that suppresses inflammation, and dacarbazine is an alkylating agent that interferes with DNA replication.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
cyclophosphamide, vincristine, prednisone, dacarbazine TARGET	cyclophosphamide, vincristine, prednisone, dacarbazine	University of Giessen	phase 3	Alkylating agent, Vinca alkaloid, Corticosteroid	Microtubules, DNA
docetaxel, cisplatin, and capecitabine	docetaxel, cisplatin, and capecitabine	Sun Yat-sen University	phase 3	Taxane, Platinum-based chemotherapeutic, Antimetabolite	Microtubules, DNA
docetaxel, nedaplatin, and capecitabine	docetaxel, nedaplatin, and capecitabine	Sun Yat-sen University	phase 3	Taxane, Platinum-based DNA crosslinker, Thymidylate synthase inhibitor	Microtubules, DNA, Thymidylate synthase
epidoxorubicine, docetaxel, cyclophosphamide	epidoxorubicine, docetaxel, cyclophosphamide	Sanofi	phase 3	anthracycline antibiotic, taxane, alkylating agent	topoisomerase II, microtubules, DNA
Gemcitabine, Vinorelbine, Eribulin, or Utidelone	Gemcitabine, Vinorelbine, Eribulin, or Utidelone	Sun Yat-sen University	phase 3	Chemotherapy combination (nucleoside analog, vinca alkaloid, microtubule inhibitor, microtubule stabilizer)	Multiple: ribonucleotide reductase, microtubules, DNA synthesis
Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab	Socazolimab+cisplatin/carboplatin+paclitaxel+Bevacizumab	Lee's Pharmaceutical Limited	phase 3	PD-1 inhibitor, VEGF inhibitor, microtubule inhibitor, platinum-based DNA crosslinking agent	PD-1, VEGF, microtubules, DNA
Vincristine + Carboplatin + Etoposide	Vincristine + Carboplatin + Etoposide	St. Jude Children's Research Hospital	phase 3	Vinca alkaloid, platinum-based alkylating agent, topoisomerase inhibitor	Microtubules, DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent, Vinca alkaloid, Corticosteroid class)

1. University of Giessen · 1 drug in this class